Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra ...

Ever wondered if Novo Nordisk’s stock is a hidden bargain or already priced for perfection? Let’s break down what’s happening beneath the surface so you can invest with clarity. The stock has seen ...

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...